Exagen Inc. (XGN) - Q2 2026 10-Q Summary
Business Context and Reporting Period
Exagen Inc. is a medical technology company focused on the AVISE® brand of diagnostic testing products for rheumatic and autoimmune diseases, primarily the AVISE® CTD test. This report covers the quarterly period ended June 30, 2026. The company operates as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $19.94 million | $17.20 million | $37.25 million | $32.70 million |
| Gross Profit | $12.22 million | $10.40 million | $22.42 million | $19.52 million |
| Gross Margin | 61.3% | 60.4% | 60.2% | 59.7% |
| Net Loss | $(3.20) million | $(4.44) million | $(7.16) million | $(8.19) million |
| Diluted EPS | $(0.13) | $(0.21) | $(0.30) | $(0.41) |
| Cash & Equivalents | $24.59 million (as of June 30, 2026) | |||
| Total Debt (Carrying Value) | $22.84 million (Current: $0.52M; Non-Current: $22.32M) | |||
| Operating Cash Flow (YTD) | $(6.43) million used |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 15.9% QoQ and 13.9% YTD, driven by an 11% increase in AVISE® CTD test volume and a 4% increase in Average Selling Price (ASP) to $446 per test.
- Profitability Improvement: Net loss narrowed significantly compared to the prior year periods due to revenue growth and improved gross margins, despite higher operating expenses.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 8.4% QoQ, primarily due to increased employee-related costs and stock-based compensation ($0.98M in Q2 2026 vs. $0.44M in Q2 2025).
- Debt Structure: The company entered a new Perceptive Term Loan Facility in April 2025. In March 2026, the facility was amended to terminate Tranche C and extend Tranche B availability. Interest expense increased due to this new facility and an embedded finance lease.
- Warrant Liability: The fair value of the warrant liability decreased by $0.46 million in Q2 2026, resulting in a non-cash gain, compared to a loss in the prior year.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing capital resources ($24.6M cash) are sufficient to fund operations for at least the next 12 months. An additional $40.0 million is available under the Perceptive Term Loan Facility subject to revenue milestones.
- Product Pipeline: The company expects to launch a Myositis offering in 2027. Development continues on Lupus Nephritis (LN) biomarkers and AI-driven algorithms for SLE and RA disease activity.
- Reimbursement Risks: Revenue depends heavily on third-party payor reimbursement. The company faces uncertainty regarding the Local Coverage Determination (LCD) for its AVISE® Lupus test due to a federal regulatory freeze on new rules.
- Supply Chain: Approximately 96% of diagnostic testing supplies for the six months ended June 30, 2026, were purchased from two suppliers, creating concentration risk.
- Debt Covenants: The Perceptive Term Loan requires maintaining a minimum unrestricted cash balance of $3.0 million and achieving specified quarterly net revenue levels. The company was in compliance as of June 30, 2026.
Investor Verification Checklist
- Verify the status of the Local Coverage Determination (LCD) application for the AVISE® Lupus test with CMS/Noridian.
- Monitor the company's ability to meet the revenue milestones required to draw the remaining $40.0 million under the Perceptive Term Loan Facility.
- Assess the impact of the new lease agreement for 28,000 sq. ft. in Carlsbad, CA (commencing May 2027) on future operating expenses.
- Review the concentration risk associated with the two primary suppliers providing 96% of diagnostic testing materials.
- Track the adoption rates and reimbursement success of the new T-Cell and RA Sub-Profile biomarkers added to the AVISE® CTD platform.